14 results on '"MacRae, Calum"'
Search Results
2. Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review.
- Author
-
Nielsen, Rikke V., Fuster, Valentin, Bundgaard, Henning, Fuster, Jose J., Johri, Amer M., Kofoed, Klaus F., Douglas, Pamela S., Diederichsen, Axel, Shapiro, Michael D., Nicholls, Stephen J., Nordestgaard, Børge G., Lindholt, Jes S., MacRae, Calum, Yuan, Chun, Newby, David E., Urbina, Elaine M., Bergström, Göran, Ridderstråle, Martin, Budoff, Matthew J., and Bøttcher, Morten
- Subjects
- *
CARDIOVASCULAR diseases , *ATHEROSCLEROSIS , *MYOCARDIAL infarction , *INDIVIDUALIZED medicine , *POPULATION health , *MEDICAL care - Abstract
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and challenges the capacity of health care systems globally. Atherosclerosis is the underlying pathophysiological entity in two-thirds of patients with CVD. When considering that atherosclerosis develops over decades, there is potentially great opportunity for prevention of associated events such as myocardial infarction and stroke. Subclinical atherosclerosis has been identified in its early stages in young individuals; however, there is no consensus on how to prevent progression to symptomatic disease. Given the growing burden of CVD, a paradigm shift is required—moving from late management of atherosclerotic CVD to earlier detection during the subclinical phase with the goal of potential cure or prevention of events. Studies must focus on how precision medicine using imaging and circulating biomarkers may identify atherosclerosis earlier and determine whether such a paradigm shift would lead to overall cost savings for global health. [Display omitted] • Early-stage subclinical atherosclerosis can be identified in young individuals, but evidence-based strategies are needed to prevent progression of disease and clinical events. • Precision medicine using imaging and circulating biomarkers could facilitate early identification of atherosclerosis and the development of curative interventions. • A paradigm shift based on these principles could reduce the global burden of CVD with enormous implications for population health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Splicing and Dilated Cardiomyopathy: One Gene to Rule Them All? ⁎ [⁎] Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
- Author
-
MacRae, Calum A. and McKenna, William J.
- Published
- 2009
- Full Text
- View/download PDF
4. Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents.
- Author
-
DeWitt, Elizabeth S, Chandler, Stephanie F, Hylind, Robyn J, Beausejour Ladouceur, Virginie, Blume, Elizabeth D, VanderPluym, Christina, Powell, Andrew J, Fynn-Thompson, Francis, Roberts, Amy E, Sanders, Stephen P, Bezzerides, Vassilios, Lakdawala, Neal K, MacRae, Calum A, and Abrams, Dominic J
- Abstract
Background: Arrhythmogenic cardiomyopathy (ACM) is a variably penetrant disease increasingly identified in young patients.Objectives: This study sought to describe the diverse phenotype, genotype, and outcomes in pediatric and adolescent patients.Methods: Records from 1999 to 2016 were reviewed for individuals age <21 years with a consistent personal or family history. Patients were categorized by right ventricular (RV), left dominant (LD), or biventricular subtypes using 2010 Task Force Criteria or proposed features of LD disease, encompassing electrocardiographic, structural, histological, and arrhythmic characteristics. Genetic variants classified as pathogenic and/or likely pathogenic by 2015 American College of Medical Genetics and Genomics criteria in recognized disease-associated genes were included.Results: Manifest disease was evident in 32 patients (age 15.1 ± 3.8 years), of whom 22 were probands, including 16 RV, 7 LD, and 9 biventricular ACM. Nondiagnostic features were seen in 5 of 15 family members. RV disease was associated with cardiac arrest and ventricular tachycardia (p = 0.02) and prevalence of PKP2 variants (p < 0.01), whereas biventricular disease was associated with a younger age of onset (p = 0.02). LD ACM was associated with variants in DSP and LMNA, and biventricular ACM with more a diverse etiology in desmosomal genes. Cardiac arrest was observed in 5 probands (age 15.3 ± 1.9 years) and ventricular tachycardia in 10 (age 16.6 ± 2.7 years), 6 probands, and 4 family members. Features suggestive of myocardial inflammation were seen in 6 patients, with ventricular tachycardia and/or cardiac arrest in 3 patients. Cardiac transplantation was performed in 10 patients. There were no deaths. In RV and biventricular disease, electrocardiographic preceded imaging features, whereas the reverse was seen in LD disease.Conclusions: ACM in the young has highly varied phenotypic expression incorporating life-threatening arrhythmia, heart failure, and myocardial inflammation. Increased awareness of early onset, aggressive disease has important implications for patient management and familial screening. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk.
- Author
-
Seidelmann, Sara B, Feofanova, Elena, Yu, Bing, Franceschini, Nora, Claggett, Brian, Kuokkanen, Mikko, Puolijoki, Hannu, Ebeling, Tapani, Perola, Markus, Salomaa, Veikko, Shah, Amil, Coresh, Josef, Selvin, Elizabeth, MacRae, Calum A, Cheng, Susan, Boerwinkle, Eric, and Solomon, Scott D
- Abstract
Background: Loss-of-function mutations in the SGLT1 (sodium/glucose co-transporter-1) gene result in a rare glucose/galactose malabsorption disorder and neonatal death if untreated. In the general population, variants related to intestinal glucose absorption remain uncharacterized.Objectives: The goal of this study was to identify functional SGLT1 gene variants and characterize their clinical consequences.Methods: Whole exome sequencing was performed in the ARIC (Atherosclerosis Risk in Communities) study participants enrolled from 4 U.S. communities. The association of functional, nonsynonymous substitutions in SGLT1 with 2-h oral glucose tolerance test results was determined. Variants related to impaired glucose tolerance were studied, and Mendelian randomization analysis of cardiometabolic outcomes was performed.Results: Among 5,687 European-American subjects (mean age 54 ± 6 years; 47% male), those who carried a haplotype of 3 missense mutations (frequency of 6.7%)-Asn51Ser, Ala411Thr, and His615Gln-had lower 2-h glucose and odds of impaired glucose tolerance than noncarriers (β-coefficient: -8.0; 95% confidence interval [CI]: -12.7 to -3.3; OR: 0.71; 95% CI: 0.59 to 0.86, respectively). The association of the haplotype with oral glucose tolerance test results was consistent in a replication sample of 2,791 African-American subjects (β = -16.3; 95% CI: -36.6 to 4.1; OR: 0.39; 95% CI: 0.17 to 0.91) and an external European-Finnish population sample of 6,784 subjects (β = -3.2; 95% CI: -6.4 to -0.02; OR: 0.81; 95% CI: 0.68 to 0.98). Using a Mendelian randomization approach in the index cohort, the estimated 25-year effect of a reduction of 20 mg/dl in 2-h glucose via SGLT1 inhibition would be reduced prevalent obesity (OR: 0.43; 95% CI: 0.23 to 0.63), incident diabetes (hazard ratio [HR]: 0.58; 95% CI: 0.35 to 0.81), heart failure (HR: 0.53; 95% CI: 0.24 to 0.83), and death (HR: 0.66; 95% CI: 0.42 to 0.90).Conclusions: Functionally damaging missense variants in SGLT1 protect from diet-induced hyperglycemia in multiple populations. Reduced intestinal glucose uptake may protect from long-term cardiometabolic outcomes, providing support for therapies that target SGLT1 function to prevent and treat metabolic conditions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
6. AN UNDERSERVED COMMUNITY-BASED HYPERTENSION CONTROL USING HEALTH WORKERS OUTREACH AND ALGORITHMIC SOFTWARE-DRIVEN BLOOD PRESSURE MANAGEMENT.
- Author
-
Deo, Rahul, Nwoko, Ogechi, Nichols, Sandra Bruce, Price, Esha, Baker, Wanda, Patel, Rahul, MacRae, Calum A., and Murillo, Jaime E.
- Subjects
- *
BLOOD pressure , *HYPERTENSION - Published
- 2023
- Full Text
- View/download PDF
7. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
- Author
-
van Kimmenade, Roland R., Januzzi, James L., Ellinor, Patrick T., Sharma, Umesh C., Bakker, Jaap A., Low, Adrian F., Martinez, Abelardo, Crijns, Harry J., MacRae, Calum A., Menheere, Paul P., and Pinto, Yigal M.
- Subjects
- *
BIOMARKERS , *HEART failure , *HEART diseases , *CARDIAC arrest - Abstract
Objectives: This study sought to explore the role of new biomarkers in heart failure (HF). Background: We investigated the utility of novel serum markers alone or together with natriuretic peptide testing for diagnosis and short-term prognosis estimation in subjects with acute HF. Methods: Plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and galectin-3 were measured in 599 patients presenting with dyspnea at the emergency department, of which 209 (35%) had acute HF. Results: The NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF, although galectin-3 levels were significantly higher in subjects with HF compared with those without. Receiver operating characteristic analysis for mortality prediction showed that, for 60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p = 0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p = 0.009) and 0.54 (p = 0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best independent predictor of 60-day mortality (odds ratio 10.3, p < 0.01) or the combination of death/recurrent HF within 60 days (odds ratio 14.3, p < 0.001). The Kaplan-Meier analyses showed that the combination of an elevated galectin-3 with NT-proBNP was a better predictor of mortality than either of the 2 markers alone. Conclusions: Our data show potential utility of galectin-3 as a useful marker for evaluation of patients with suspected or proven acute HF, whereas apelin measurement was not useful for these indications. Moreover, the combination of galectin-3 with NT-proBNP was the best predictor for prognosis in subjects with acute HF. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
8. A Novel Locus for Dilated Cardiomyopathy, Diffuse Myocardial Fibrosis, and Sudden Death on Chromosome 10q25-26
- Author
-
Ellinor, Patrick T., Sasse-Klaassen, Sabine, Probst, Susanne, Gerull, Brenda, Shin, Jordan T., Toeppel, Andrea, Heuser, Arnd, Michely, Beate, Yoerger, Danita M., Song, Bong-Seok, Pilz, Bernhard, Krings, Gregor, Coplin, Bruce, Lange, Peter E., Dec, G. William, Hennies, Hans Christian, Thierfelder, Ludwig, and MacRae, Calum A.
- Subjects
- *
CARDIOMYOPATHIES , *CHROMOSOMES , *PHENOTYPES , *MEDICAL genetics , *HEREDITY , *HEART failure , *ETIOLOGY of diseases , *GENETICS - Abstract
Objectives: We sought to identify the genetic locus for an inherited form of dilated cardiomyopathy (DCM) that is characterized by diffuse myocardial fibrosis and sudden death. Background: Genetic studies have mapped multiple loci for DCM, which is a major cause of nonischemic heart failure; however, the genes responsible for the majority of cases have yet to be identified. Methods: Sixty-six family members were evaluated by 12-lead electrocardiogram (ECG), echocardiogram, and laboratory studies. Individuals with echocardiographically documented DCM were defined as affected. Subjects were considered unaffected if they were older than 20 years of age, had a normal ECG and echocardiogram, no personal history of heart failure, and had no affected offspring. Genotyping was performed using polymorphic markers. Results: Genome-wide linkage analysis identified a novel locus for this inherited phenotype on chromosome 10q25.3-q26.13. Peak two-point logarithm of the odds scores >3.0 were obtained independently with each family using the markers D10S1773 and D10S1483, respectively. Haplotype analyses defined a critical interval of 14.0 centiMorgans between D10S1237 and D10S1723, corresponding to a physical distance of 9.5 megabases. Multipoint linkage analyses confirmed this interval and generated a peak logarithm of the odds score of 8.2 indicating odds of >100,000,000:1 in favor of this interval as the location of the gene defect responsible for DCM in these families. Conclusions: We have mapped a novel locus for cardiomyopathy, diffuse myocardial fibrosis, and sudden death to chromosome 10q25-q26. The identification of the causative gene in this interval will be an important step in understanding the fundamental mechanisms of heart failure and sudden death. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
9. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: Natural history
- Author
-
Murphy, Ross T., Mogensen, Jens, McGarry, Kate, Bahl, Ajay, Evans, Alison, Osman, Eyman, Syrris, Petros, Gorman, Grainne, Farrell, Michael, Holton, Janice L., Hanna, Michael G., Hughes, Sian, Elliott, Perry M., MacRae, Calum A., and McKenna, William J.
- Subjects
- *
PARKINSON'S disease , *ADENOSINES , *CHEST disease diagnosis , *PROTEIN kinases - Abstract
Objectives: The aim of this study was to investigate the clinical expression of adenosine monophosphate-activated protein kinase (AMPK) gene mutations (PRKAG2) in adenosine monophosphate (AMP) kinase disease based on 12 years follow-up of known mutation carriers and to define the prevalence of PRKAG2 mutations in hypertrophic cardiomyopathy (HCM).Background: Adenosine monophosphate-activated protein kinase gene mutations cause HCM with Wolff-Parkinson-White syndrome and conduction disease.Methods: Clinical evaluation of 44 patients with known AMP kinase disease was analyzed. Mutation analysis of PRKAG2 was performed by fluorescent single-strand confirmation polymorphism analysis and direct sequencing of abnormal conformers in 200 patients with HCM.Results: Only one additional mutation was identified. The mean age at clinical diagnosis in the 45 gene carriers was 24 years (median 20 years, range 9 to 55 years). Symptoms of palpitation, dypspnea, chest pain, or syncope were present in 31 (69%) gene carriers; 7 (15%) complained of myalgia and had clinical evidence of proximal myopathy. Skeletal muscle biopsy showed excess mitochondria and ragged red fibers with minimal glycogen accumulation. Disease penetrance defined by typical electrocardiogram abnormalities was 100% by age 18 years. Thirty-two of 41 adults (78%) had left ventricular hypertrophy (LVH) on echocardiography, and progressive LVH was documented during follow-up. Survival was 91% at a mean follow-up of 12.2 years. Progressive conduction disease required pacemaker implantation in 17 of 45 (38%) at a mean age of 38 years.Conclusions: The AMP kinase disease is uncommon in HCM and is characterized by progressive conduction disease and cardiac hypertrophy and includes extracardiac manifestations such as a skeletal myopathy, consistent with a systemic metabolic storage disease. Defects in adenosine triphosphate utilization or in specific cellular substrates, rather than mere passive deposition of amylopectin, may account for these clinical features. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
10. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation
- Author
-
Ellinor, Patrick T., Low, Adrian F., Patton, Kristen K., Shea, Marisa A., and MacRae, Calum A.
- Subjects
- *
ATRIAL fibrillation , *ATRIAL arrhythmias , *ATRIAL natriuretic peptides , *BIOMARKERS - Abstract
Objectives: We sought to characterize natriuretic peptide levels in a cohort of rigorously characterized subjects with lone atrial fibrillation (AF). Background: Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are sensitive biomarkers of cardiac contractile dysfunction. Both peptides have been reported to be elevated in cohorts with AF, but previous studies have included subjects with underlying structural heart disease. We studied these hormones in 150 subjects with lone AF. Methods: Study subjects had electrocardiographic evidence of at least one episode of AF and a structurally normal heart on echocardiography. Subjects were excluded if they had a history of a myocardial infarction, rheumatic heart disease, cardiomyopathy, significant valvular disease, hyperthyroidism, or hypertension that preceded the onset of AF. Control subjects were obtained from a healthy outpatient primary care population. Plasma pro-ANP and N-terminal pro-BNP (nt-pro-BNP) levels were determined using commercially available immunoassays. Results: A total of 150 serial subjects with lone AF were enrolled and studied, the majority during normal sinus rhythm. Median levels of nt-pro-BNP were significantly elevated in subjects with lone AF as compared with control subjects (166 vs. 133 fmol/ml, p = 0.0003). There was no significant difference in pro-ANP levels between subjects with lone AF and control subjects (1,730 vs. 1,625 fmol/ml, p = 0.90). Conclusions: Discordant natriuretic peptide levels were observed in this homogeneous population of subjects with lone AF. This biomarker pattern, which is present even in sinus rhythm, may represent an underlying subclinical predisposition to this common arrhythmia. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
11. DISRUPTION OF LAMIN A LEADS TO EARLY-ONSET CARDIAC CONDUCTION DYSFUNCTION IN ZEBRAFISH MODELS OF LAMINOPATHY.
- Author
-
Teramoto, Ryota, Hayashi, Kenshi, Beerens, Manu, Burch, Micah, Chiang, David, Kithcart, Aaron P., Zu, Yao, Kiviniemi, Tuomas, Buys, Eva, Nomura, Akihiro, Takamura, Masayuki, and MacRae, Calum A.
- Subjects
- *
BRACHYDANIO , *DILATED cardiomyopathy , *CARDIAC output - Published
- 2020
- Full Text
- View/download PDF
12. A REMOTE LIPID MANAGEMENT PROGRAM IMPROVES APPROPRIATE STATIN USE AND CHOLESTEROL LEVELS ACROSS A WIDE POPULATION OF HIGH CARDIOVASCULAR RISK PATIENTS.
- Author
-
Benson, Mark D., McPartlin, Marian, Matta, Lina, Kraft, Michael, Barclay, Kira C., Bui, Tiffany V., Blackburn, Robert W., Zelle, David, Mercurio-Pinto, Ana, Gaziano, Thomas, MacRae, Calum, Scirica, Benjamin, and Plutzky, Jorge
- Published
- 2018
- Full Text
- View/download PDF
13. BRIGHAM PROTOCOL-BASED HYPERTENSION OPTIMIZATION PROGRAM (BP-HOP).
- Author
-
Fisher, Naomi, Smolinsky, Liliana, Pagliaro, Jaclyn, Desai, Sonali, Matta, Lina, Scirica, Benjamin, and MacRae, Calum
- Published
- 2018
- Full Text
- View/download PDF
14. BESIDE TOOLS FOR STRATIFICATION OF THE ETIOLOGY OF CARDIAC HYPERTROPHY.
- Author
-
Kapur, Sunil, Beik, Samantha P., Prem, Sneha, and MacRae, Calum
- Subjects
- *
CARDIAC hypertrophy , *ETIOLOGY of diseases , *SOCIAL stratification , *HEALTH outcome assessment , *CARDIOLOGY - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.